{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T09:29:36Z","timestamp":1768123776998,"version":"3.49.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.gofs.2017.08.002","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T06:00:21Z","timestamp":1505973621000},"page":"535-544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact de la r\u00e9ponse histologique compl\u00e8te \u00e0 la chimioth\u00e9rapie n\u00e9o-adjuvante pour cancer du sein selon le sous-type mol\u00e9culaire"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2756-4060","authenticated-orcid":false,"given":"J.","family":"Cirier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Body","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-L.","family":"Jourdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bedouet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fleurier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Pilloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Arbion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ouldamer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10\u201311","key":"10.1016\/j.gofs.2017.08.002_bib0270","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s10269-011-2075-z","article-title":"Les traitements n\u00e9oadjuvants (hors cancer du sein inflammatoire)","volume":"13","author":"Ceugnart","year":"2011","journal-title":"Oncologie"},{"issue":"12","key":"10.1016\/j.gofs.2017.08.002_bib0275","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10269-013-2348-9","article-title":"Les traitements n\u00e9oadjuvants TNA (RPC\u00a02013)","volume":"15","author":"Salmon","year":"2013","journal-title":"Oncologie"},{"issue":"Suppl. 5","key":"10.1016\/j.gofs.2017.08.002_bib0280","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gofs.2017.08.002_bib0285","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring therapies \u2013 improving the management of early breast cancer: St Gallen International expert consensus on the primary therapy of early breast cancer 2015","author":"Coates","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gofs.2017.08.002_bib0290","series-title":"Cochrane database of systematic reviews [Internet]","article-title":"Preoperative chemotherapy for women with operable breast cancer","author":"van der Hage","year":"2007"},{"issue":"30","key":"10.1016\/j.gofs.2017.08.002_bib0295","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","article-title":"Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project\u00a0B-18","volume":"2001","author":"Wolmark","year":"2001","journal-title":"JNCI Monogr"},{"issue":"3","key":"10.1016\/j.gofs.2017.08.002_bib0300","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jnci\/dji021","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis","volume":"97","author":"Mauri","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.gofs.2017.08.002_bib0305","doi-asserted-by":"crossref","first-page":"e469251","DOI":"10.1155\/2014\/469251","article-title":"Breast cancer survival defined by the ER\/PR\/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers","volume":"2014","author":"Parise","year":"2014","journal-title":"J Cancer Epidemiol"},{"issue":"2","key":"10.1016\/j.gofs.2017.08.002_bib0310","first-page":"520","article-title":"HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors","volume":"8","author":"M\u00e9nard","year":"2002","journal-title":"Am Assoc Cancer Res"},{"issue":"2","key":"10.1016\/j.gofs.2017.08.002_bib0315","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000292644","article-title":"The changing role of pathology in breast cancer diagnosis and treatment","volume":"78","author":"Leong","year":"2011","journal-title":"Pathobiology"},{"issue":"7","key":"10.1016\/j.gofs.2017.08.002_bib0320","first-page":"663","article-title":"[Place of anatomopathology in evaluation of response to neoadjuvant chemotherapy. Prognostic and predictive markers: example of breast cancer]","volume":"93","author":"Abrial","year":"2006","journal-title":"Bull Cancer (Paris)"},{"issue":"1","key":"10.1016\/j.gofs.2017.08.002_bib0325","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.critrevonc.2015.02.011","article-title":"Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?","volume":"95","author":"Wang-Lopez","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.gofs.2017.08.002_bib0330","unstructured":"CIM-10 FR 2015 \u00e0 usage PMSI | Publication ATIH [Internet]. [cited 2016 Sep 6]. Available from: http:\/\/www.atih.sante.fr\/cim-10-fr-2015-usage-pmsi."},{"key":"10.1016\/j.gofs.2017.08.002_bib0335","unstructured":"Haute Autorit\u00e9 de sant\u00e9 - Hypercholest\u00e9rol\u00e9mie pure et hyperlipid\u00e9mie mixte\u00a0: prise en charge - Note de cadrage [Internet]. [cited 2016 Sep 6]. Available from: http:\/\/www.has-sante.fr\/portail\/jcms\/c_2039802\/fr\/hypercholesterolemie-pure-et-hyperlipidemie-mixte-prise-en-charge-note-de-cadrage."},{"issue":"2","key":"10.1016\/j.gofs.2017.08.002_bib0340","first-page":"144","volume":"16","author":"Balaton","year":"1996","journal-title":"Ann Pathol"},{"issue":"31","key":"10.1016\/j.gofs.2017.08.002_bib0345","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for Human epidermal growth factor receptor\u00a02 testing in breast cancer: American society of clinical oncology\/College of American pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gofs.2017.08.002_bib0350","unstructured":"Molecular portraits of human breast tumours: Article: Nature [Internet]. Available from: http:\/\/www.nature.com\/nature\/journal\/v406\/n6797\/full\/406747a0.html."},{"key":"10.1016\/j.gofs.2017.08.002_bib0355","unstructured":"The role of the pathological Complete Response as an endpoint in neoadjuvant breast cancer studies. Condition - specific guidance, Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man. [Internet]. EMA: European Medicines Agency; 2014. Available from: http:\/\/www.ema.europa.eu\/ema\/pages\/includes\/document\/open_document.jsp?webContentId=WC500195216."},{"key":"10.1016\/j.gofs.2017.08.002_bib0360","unstructured":"Logiciel\u00a0R version\u00a03.1.2 (package Hmisc, Design and Survival libraries) [Internet]. Available from: http:\/\/www.cran.r-project.org\/."},{"issue":"3","key":"10.1016\/j.gofs.2017.08.002_bib0365","first-page":"297","article-title":"Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome","volume":"180","author":"Sataloff","year":"1995","journal-title":"J Am Coll Surg"},{"issue":"3","key":"10.1016\/j.gofs.2017.08.002_bib0370","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00000421-199306000-00006","article-title":"Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate","volume":"16","author":"Chevallier","year":"1993","journal-title":"Am J Clin Oncol"},{"issue":"8","key":"10.1016\/j.gofs.2017.08.002_bib0375","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.humpath.2007.11.019","article-title":"Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer","volume":"39","author":"Penault-Llorca","year":"2008","journal-title":"Hum Pathol"},{"issue":"28","key":"10.1016\/j.gofs.2017.08.002_bib0380","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2017.08.002_bib0385","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-010-0939-3","article-title":"A multicenter randomized phase\u00a0II study of sequential epirubicin\/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients","volume":"122","author":"Pierga","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"10.1016\/j.gofs.2017.08.002_bib0390","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","article-title":"Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor\u00a02 \u2013 Positive operable breast cancer","volume":"23","author":"Buzdar","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.gofs.2017.08.002_bib0395","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1200\/JCO.2005.02.8886","article-title":"Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor\u00a02 \u2013 Positive locally advanced breast cancer","volume":"24","author":"Hurley","year":"2006","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.gofs.2017.08.002_bib0400","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jjco\/hyp052","article-title":"Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor\u00a02 \u2013 Positive primary breast cancer","volume":"39","author":"Shimizu","year":"2009","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2017.08.002_bib0405","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/annonc\/mdq406","article-title":"Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer","volume":"22","author":"Wildiers","year":"2011","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2017.08.002_bib0410","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.breast.2014.10.008","article-title":"Pathologic complete response rates in triple-negative. HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab","volume":"24","author":"Shinde","year":"2015","journal-title":"The Breast"},{"issue":"12","key":"10.1016\/j.gofs.2017.08.002_bib0415","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","article-title":"Neoadjuvant treatment with trastuzumab in HER2 \u2013 Positive breast cancer: results from the GeparQuattro study","volume":"28","author":"Untch","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.gofs.2017.08.002_bib0420","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.breast.2014.03.008","article-title":"Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status","volume":"23","author":"Tanioka","year":"2014","journal-title":"The Breast"},{"issue":"1","key":"10.1016\/j.gofs.2017.08.002_bib0425","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase\u00a02 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.gofs.2017.08.002_bib0430","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase\u00a0II cardiac safety study (Tryphaena)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"6, Suppl. 1","key":"10.1016\/j.gofs.2017.08.002_bib0435","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S0007-4551(16)30149-7","article-title":"Chimioth\u00e9rapie n\u00e9o-adjuvante des cancers du sein HER2-positifs et triple-n\u00e9gatifs","volume":"103","author":"Gon\u00e7alves","year":"2016","journal-title":"Bull Cancer (Paris)"},{"issue":"15","key":"10.1016\/j.gofs.2017.08.002_bib0440","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9938","key":"10.1016\/j.gofs.2017.08.002_bib0445","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/j.gofs.2017.08.002_bib0450","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/sj.bjc.6602235","article-title":"Estrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer","volume":"91","author":"Ring","year":"2004","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.gofs.2017.08.002_bib0455","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1200\/JCO.2005.02.6914","article-title":"Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors","volume":"24","author":"Guarneri","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gofs.2017.08.002_bib0460","doi-asserted-by":"crossref","unstructured":"Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. The Lancet 375(9712):377\u201384.","DOI":"10.1016\/S0140-6736(09)61964-4"},{"issue":"19","key":"10.1016\/j.gofs.2017.08.002_bib0465","first-page":"6622","article-title":"Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors","volume":"10","author":"Colleoni","year":"2004","journal-title":"Am Assoc Cancer Res"},{"issue":"8","key":"10.1016\/j.gofs.2017.08.002_bib0470","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.gofs.2017.08.002_bib0475","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s12094-008-0265-y","article-title":"Tumour molecular subtyping according to hormone receptors and HER-2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer","volume":"10","author":"S\u00e1nchez-Mu\u00f1oz","year":"2008","journal-title":"Clin Transl Oncol"},{"issue":"7","key":"10.1016\/j.gofs.2017.08.002_bib0480","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.gofs.2017.08.002_bib0485","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1002\/cncr.26555","article-title":"Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer","volume":"118","author":"Bayraktar","year":"2012","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.gofs.2017.08.002_bib0490","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","article-title":"Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups","volume":"29","author":"Untch","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2017.08.002_bib0495","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10549-013-2497-y","article-title":"The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144\u00a0patients","volume":"138","author":"Hurley","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.gofs.2017.08.002_bib0500","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.breast.2012.07.012","article-title":"Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study","volume":"22","author":"Guiu","year":"2013","journal-title":"Breast Edinb Scotl"},{"key":"10.1016\/j.gofs.2017.08.002_bib0505","unstructured":"Senechal C, Reyal F, Malhaire C, Marchand V, Bidard FC, Sigal B, Pierga JY. Chimioth\u00e9rapie n\u00e9o-adjuvante des cancers du sein. Lett Cancerologue [Internet] 2011; 7. Available from: http:\/\/www.edimark.fr\/lettre-cancerologue\/chimiotherapie-neo-adjuvante-cancers-sein [cited 2016 Aug 21]."},{"issue":"7","key":"10.1016\/j.gofs.2017.08.002_bib0510","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/sj.bjc.6600210","article-title":"Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer","volume":"86","author":"Chollet","year":"2002","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.gofs.2017.08.002_bib0515","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","article-title":"Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy","volume":"17","author":"Kuerer","year":"1999","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2017.08.002_bib0520","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10549-005-9008-8","article-title":"High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710\u00a0patients with operable breast cancer","volume":"94","author":"Amat","year":"2005","journal-title":"Breast Cancer Res Treat"},{"issue":"36","key":"10.1016\/j.gofs.2017.08.002_bib0525","doi-asserted-by":"crossref","first-page":"9304","DOI":"10.1200\/JCO.2005.02.5023","article-title":"Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy","volume":"23","author":"Hennessy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.gofs.2017.08.002_bib0265","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2008.19.2567","article-title":"Phase\u00a0III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European cooperative trial in operable breast cancer","volume":"27","author":"Gianni","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718917301952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718917301952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T03:50:17Z","timestamp":1659498617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468718917301952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S2468718917301952"],"URL":"https:\/\/doi.org\/10.1016\/j.gofs.2017.08.002","relation":{},"ISSN":["2468-7189"],"issn-type":[{"value":"2468-7189","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact de la r\u00e9ponse histologique compl\u00e8te \u00e0 la chimioth\u00e9rapie n\u00e9o-adjuvante pour cancer du sein selon le sous-type mol\u00e9culaire","name":"articletitle","label":"Article Title"},{"value":"Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gofs.2017.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}